People · Operator

JOHN C. MARTIN

Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology

1
Companies
1
Filings
$430.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Sarepta Therapeutics, Inc.BiotechnologySeries D+$430.5M$16.5B2020
Operator network

JOHN C. MARTIN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Douglas S. Ingram · 3 companies · 1 sharedDouglas S. IngramRICHARD J. BARRY · 3 companies · 1 sharedRICHARD J. BARRYDavid Tyronne Howton · 2 companies · 1 sharedDavid Tyronne How…ALEXANDER S. CUMBO · 1 companies · 1 sharedALEXANDER S. CUMBOCLAUDE W. NICAISE · 1 companies · 1 sharedCLAUDE W. NICAISEGILMORE TYRONNE O'NEILL · 1 companies · 1 sharedGILMORE TYRONNE O…HANS W. WIGZELL · 1 companies · 1 sharedHANS W. WIGZELLMARY ANN W. GRAY · 1 companies · 1 sharedMARY ANN W. GRAYMICHAEL W. BONNEY · 1 companies · 1 sharedMICHAEL W. BONNEYM. KATHLEEN BEHRENS · 1 companies · 1 sharedM. KATHLEEN BEHRE…SANDESH TYRONNE MAHATME · 1 companies · 1 sharedSANDESH TYRONNE M…WILLIAM TYRONNE CIAMBRONE · 1 companies · 1 sharedWILLIAM TYRONNE C…WILLIAM W. CIAMBRONE · 1 companies · 1 sharedWILLIAM W. CIAMBR…Sarepta Therapeutics, Inc. · $430.5M raisedSarepta Therapeutics,…JOHN C. MARTINJM
JOHN C. MARTIN Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside JOHN C. MARTIN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Douglas S. Ingram13
RICHARD J. BARRY13
David Tyronne Howton12
MICHAEL W. BONNEY11
MARY ANN W. GRAY11
CLAUDE W. NICAISE11
HANS W. WIGZELL11
ALEXANDER S. CUMBO11
SANDESH TYRONNE MAHATME11
GILMORE TYRONNE O'NEILL11
WILLIAM TYRONNE CIAMBRONE11
M. KATHLEEN BEHRENS11
WILLIAM W. CIAMBRONE11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.